Article

AAO 2019 Retina Street Team: J. Fernando Arevalo, MD, FACS

J. Fernando Arevalo, MD, FACS, shares findings from his presentation on using brolucizumab to treat neovascular age-related macular degeneration (AMD), and whether the novel therapy is better than current treatment, at the 2019 annual meeting of the American Academy of Ophthalmology in San Francisco.

Day 3 of the 2019 annual meeting of the American Academy of Ophthalmology features Fernando Arevalo, MD, FACS, as he shares findings from his presentation on using brolucizumab to treat neovascular age-related macular degeneration (AMD), and whether the novel therapy is better than current treatment. 

Read and watch more AAO 2019 Retina Street Team coverage here

Related Videos
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
© 2025 MJH Life Sciences

All rights reserved.